HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.

Abstract
Invasive fungal infection (IFI) is a leading cause of infection-related mortality among patients with cancer and prolonged neutropenia and among allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Invasive candidiasis was the principal IFI in the period predating fluconazole prophylaxis, whereas today, invasive aspergillosis and other mold infections cause the majority of deaths from fungal infection in this patient population. The changing epidemiology of IFI, in addition to advances made in antifungal therapeutics and early diagnosis of IFI, warrant a reevaluation of earlier strategies aimed at prevention and early treatment of IFI that were developed several years ago. Here, we propose that persistent neutropenic fever is nonspecific for an IFI and should not be used as the sole criterion for empirical modification in the antifungal regimen in a patient receiving mold-active prophylaxis. We explore the potential benefits and gaps in knowledge associated with employing chest CT scans and laboratory markers as diagnostic adjuncts for IFI. Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies.
AuthorsBrahm H Segal, Nikolaos G Almyroudis, Minoo Battiwalla, Raoul Herbrecht, John R Perfect, Thomas J Walsh, John R Wingard
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 44 Issue 3 Pg. 402-9 (Feb 01 2007) ISSN: 1537-6591 [Electronic] United States
PMID17205448 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Biomarkers
  • Mannans
  • beta-Glucans
  • galactomannan
  • Galactose
Topics
  • Antifungal Agents (therapeutic use)
  • Biomarkers (blood)
  • Evaluation Studies as Topic
  • Fever (etiology, microbiology)
  • Fungi (drug effects, pathogenicity)
  • Galactose (analogs & derivatives)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Mannans (blood)
  • Mycoses (diagnosis, drug therapy, prevention & control)
  • Neoplasms (complications, microbiology)
  • Neutropenia (etiology, microbiology)
  • Practice Guidelines as Topic (standards)
  • Randomized Controlled Trials as Topic
  • Tomography, X-Ray Computed
  • Yeasts (drug effects, pathogenicity)
  • beta-Glucans (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: